Literature DB >> 6432846

Selective inhibition of human diploid fibroblast collagen synthesis by interferons.

S A Jimenez, B Freundlich, J Rosenbloom.   

Abstract

The effects of alpha- and gamma-interferons (IFNs) on collagen production by confluent human diploid fibroblasts in culture were examined. It was found that partially purified alpha-IFNs and affinity purified gamma-IFNs caused greater than 50% inhibition of collagen synthesis by these cells independently of their effect on cell proliferation. Recombinant alpha-IFNs showed a similar effect (38.8% inhibition), indicating that collagen synthesis inhibition was a constitutive property of IFNs. Collagen synthesis inhibition by IFNs was concentration dependent. Gel filtration chromatography of the newly synthesized proteins from the media of fibroblasts incubated with partially purified alpha-IFNs demonstrated a selective depression of molecules eluting in the region of procollagen. No detectable increase in collagen degradation products or underhydroxylation of procollagen was observed. Short-term kinetic studies further demonstrated that the major effect of IFNs was due to a net decrease in fibroblast collagen production rather than to impairment of secretion or increased extracellular degradation of the newly synthesized molecules. These results indicate that alpha- and gamma-IFNs are potent inhibitors of human fibroblast collagen production and suggest that they may play an important role in the regulation of normal and pathologic fibrogenesis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432846      PMCID: PMC425272          DOI: 10.1172/JCI111480

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  10 in total

1.  Lymphokine stimulation of collagen accumulation.

Authors:  R L Johnson; M Ziff
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

2.  Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast.

Authors:  E C LeRoy
Journal:  J Clin Invest       Date:  1974-10       Impact factor: 14.808

3.  Convenient assay for interferons.

Authors:  S Rubinstein; P C Familletti; S Pestka
Journal:  J Virol       Date:  1981-02       Impact factor: 5.103

4.  Lymphocyte-mediated activation of fibroblast proliferation and collagen production.

Authors:  S M Wahl; L M Wahl; J B McCarthy
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

5.  Purification and characterization of interferons from a continuous myeloblastic cell line.

Authors:  D S Hobbs; S Pestka
Journal:  J Biol Chem       Date:  1982-04-25       Impact factor: 5.157

6.  Mononuclear cell factors that inhibit fibroblast collagen synthesis. I. In vitro conditions determining their production and expression.

Authors:  P H Hart; L W Powell; W G Cooksley; J W Halliday
Journal:  Scand J Immunol       Date:  1983-07       Impact factor: 3.487

7.  Lymphokine modulation of fibroblast proliferation.

Authors:  E G Nielson; S M Phillips; S Jimenez
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

8.  Modified procedure for the assay of H-3-or C-14-labeled hydroxyproline.

Authors:  K Juva; D J Prockop
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

9.  Inhibition of collagen synthesis by mononuclear cell supernates.

Authors:  S A Jimenez; W McArthur; J Rosenbloom
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

10.  Alterations in collagen production in mixed mononuclear leukocyte-fibroblast cultures.

Authors:  M S Hibbs; A E Postlethwaite; C L Mainardi; J M Seyer; A H Kang
Journal:  J Exp Med       Date:  1983-01-01       Impact factor: 14.307

  10 in total
  53 in total

Review 1.  The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide.

Authors:  S J Oliver
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

2.  Innovative therapies in the treatment of keloids and hypertrophic scars.

Authors:  Martha H Viera; Sadegh Amini; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-05

Review 3.  Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies.

Authors:  Gerd G Gauglitz; Hans C Korting; Tatiana Pavicic; Thomas Ruzicka; Marc G Jeschke
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

4.  The effect of in vivo T helper and T suppressor lymphocyte depletion on wound healing.

Authors:  A Barbul; R J Breslin; J P Woodyard; H L Wasserkrug; G Efron
Journal:  Ann Surg       Date:  1989-04       Impact factor: 12.969

Review 5.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 6.  The pathogenesis of systemic sclerosis revisited.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

7.  Screening of potent inhibitors of collagen synthesis in cultured human skin fibroblasts.

Authors:  H Yamada; T Shigematsu; S Tajima; T Nishikawa
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

8.  The transcription of human alpha 1(I) procollagen gene (COL1A1) is suppressed by tumour necrosis factor-alpha through proximal short promoter elements: evidence for suppression mechanisms mediated by two nuclear-factorbinding sites.

Authors:  K Mori; A Hatamochi; H Ueki; A Olsen; S A Jimenez
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

Review 9.  Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions.

Authors:  Saeid Amini-Nik; Yusef Yousuf; Marc G Jeschke
Journal:  Adv Drug Deliv Rev       Date:  2017-07-27       Impact factor: 15.470

10.  Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.

Authors:  Soocheol Jeong; Hiroshi Aikata; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Hiromi Saneto; Kiminori Uka; Nami Mori; Shintaro Takaki; Hideaki Kodama; Koji Waki; Michio Imamura; Hiroo Shirakawa; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.